Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jeff M MichalskiPaul A Northcott

Abstract

Children with average-risk medulloblastoma (MB) experience survival rates of ≥ 80% at the expense of adverse consequences of treatment. Efforts to mitigate these effects include deintensification of craniospinal irradiation (CSI) dose and volume. ACNS0331 (ClinicalTrials.gov identifier: NCT00085735) randomly assigned patients age 3-21 years with average-risk MB to receive posterior fossa radiation therapy (PFRT) or involved field radiation therapy (IFRT) following CSI. Young children (3-7 years) were also randomly assigned to receive standard-dose CSI (SDCSI; 23.4 Gy) or low-dose CSI (LDCSI; 18 Gy). Post hoc molecular classification and mutational analysis contextualized outcomes according to known biologic subgroups (Wingless, Sonic Hedgehog, group 3, and group 4) and genetic biomarkers. Neurocognitive changes and ototoxicity were monitored over time. Five hundred forty-nine patients were enrolled on study, of which 464 were eligible and evaluable to compare PFRT versus IFRT and 226 for SDCSI versus LDCSI. The five-year event-free survival (EFS) was 82.5% (95% CI, 77.2 to 87.8) and 80.5% (95% CI, 75.2 to 85.8) for the IFRT and PFRT regimens, respectively, and 71.4% (95% CI, 62.8 to 80) and 82.9% (95% CI, 75.6 to 90.2) for the ...Continue Reading

References

Sep 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SilberA T Meadows
Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·C A Sklar, L S Constine
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J PackerJ M Boyett
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P R ThomasL E Kun
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J PackerT Moshang
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M D RisJ M Boyett
Sep 12, 2001·Neuro-oncology·T E MerchantS A Leibel
Feb 19, 2002·International Journal of Radiation Oncology, Biology, Physics·Eugene HuangShiao Y Woo
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L WoldenSteven A Leibel
Mar 29, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaret C ThompsonRichard J Gilbertson
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger J PackerRichard Sposto
Sep 9, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A NorthcottMichael D Taylor
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yoon-Jae ChoScott L Pomeroy
Dec 3, 2011·Acta Neuropathologica·Michael D TaylorStefan M Pfister
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Birgitta LanneringRolf Kortmann
Jul 21, 2017·Nature·Paul A NorthcottPeter Lichter
Mar 15, 2018·Nature·David CapperStefan M Pfister

❮ Previous
Next ❯

Citations

Oct 30, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sahaja AcharyaThomas E Merchant

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.